Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 18/20 | 0.55 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.44 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.40 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10165050 | 0.91 | PDE4D (0.67) | PDE4D | |
| SCHEMBL10165068 | 0.79 | PDE4D (0.64) | PDE4D | |
| SCHEMBL10165074 | 0.77 | PDE4D (0.52) | PDE4D | |
| SCHEMBL508953 | 0.72 | PDE4D (0.50) | PDE4D | |
| SCHEMBL509735 | 0.71 | PDE4D (1.00) | PDE4D | |
| Bicarbonate SCHEMBL17554775 | 0.69 | PDE4D (0.96) | PDE4D | |
| SCHEMBL507940 | 0.69 | PDE4D (0.82) | PDE4D | |
| SCHEMBL509513 | 0.68 | PDE4D (0.48) | PDE4D | |
| SCHEMBL508964 | 0.67 | PDE4D (0.76) | PDE4D | |
| SCHEMBL3861503 | 0.66 | KAT6A (0.56) | PDE4DDYRK1AMKNK1MKNK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8952162-B2 | Triazolopyridines as phosphodiesterase inhibitors for treatment of dermal diseases | LEO PHARMA A/S (DK) | 2015-02-10 | — | — | US | disclosed |
| US-8952162-B2 | Triazolopyridines as phosphodiesterase inhibitors for treatment of dermal diseases | LEO PHARMA A/S (DK) | 2015-02-10 | — | — | US | disclosed |
| US-20120028974-A1 | TRIAZOLOPYRIDINES AS PHOSPHODIESTERASE INHIBITORS FOR TREATMENT OF DERMAL DISEASES | LEO PHARMA A/S (DK) | 2012-02-02 | — | — | US | disclosed |
| US-20120028974-A1 | TRIAZOLOPYRIDINES AS PHOSPHODIESTERASE INHIBITORS FOR TREATMENT OF DERMAL DISEASES | LEO PHARMA A/S (DK) | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028974-A1 | TRIAZOLOPYRIDINES AS PHOSPHODIESTERASE INHIBITORS FOR TREATMENT OF DERMAL DISEASES | PDE4A, PDE4B, PDE5A | PDE4D 5/4885DYRK1A 900/4885MKNK1 3423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.